N/A N=20 Immune Responses With Reduxium
Immune Tolerance · Viral Infection
Primary: Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake — 60.53; 60; 59.29; 56.52 percentage of cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=10 Immune Response to Shingles Vaccination
Shingles
Primary: Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood — 0.02 percentage of CD4 T cells
N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
N/A N=33 Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
N/A N=107 Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Influenza
Primary: Determination of Immune Response to Vaccination. — 45 participants
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
N/A N=46 Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)
Infections, Clostridium Difficile
Primary: Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14 — 2083.3; 3189.4; 32096.4 EU/mL — p=0.5746
Phase 4 N=280 Immunomodulation Following Transfusion
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
Phase 2 N=46 Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
Healthy Volunteers
Primary: Virus Infection — 8; 18 Participants
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 2 N=34 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
Cholera
Primary: Level of Antibody Titers in Serum — 76; 2671 Vibriocidal antibody titer
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Phase 4 N=13 The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants
N/A N=28 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
RSV Infection
Primary: Number of Participants With Challenge-related Adverse Events — 0; 3 Participants
N/A N=10 Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
Hepatitis C
Primary: Number of Participants Who Completed Standard Treatment — 10; 0 participants
N/A N=20 Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
N/A N=308 COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
Phase 1 N=127 Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Inflammatory Bowel Disease
Primary: Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74 — 88.5; 90.3 percentage of participants
N/A N=10 Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
Hepatitis B
Primary: Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction). — 138; 138; 102; 81 number of genes at p<0.05
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Early Phase 1 N=172 Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
Cognitive Side Effects of Cancer Therapy · Depression · Recurrent Breast Carcinoma
Primary: AUC Change in Level of IL-6 — 5.23; 10.17 ug*hour/ml
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 4 N=20 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 20 Participants
Phase 1 N=89 Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants
Focus: Nutritional Requirements for Infants
Primary: Number of Antigen-presenting B Cells — 21.9; 22.8; 25.1 percentage of CD20+ B cells
Phase 4 N=131 Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Immune Response to Influenza Vaccine · Influenza A Virus Infection · Influenza B Virus Infection
Primary: Hemagglutination Inhibition (HI) Titer Response to Vaccine and Circulating Strains of Influenza — 99; 295; 96; 100 Titers
N/A N=133 Selenium and Immune Function
Healthy
Primary: Cellular and Humoral Immune Response — 0.29; 0.34; 0.34; 0.29 umol/min — p=<0.05